Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARQ-234 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| ARQ-234 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ARQ-234 | BIOLOGICAL | ARQ-234 subcutaneous injectable solution |
| Placebo | DRUG | Placebo subcutaneous injectable solution |
Inclusion Criteria (All Participants): * Able and willing to provide written informed consent. * Adults 18-65 years (inclusive) at consent. * Generally healthy at screening/baseline (no clinically significant findings on medical history, exam, vitals, ECG, or safety labs, per investigator). * Contr...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 6 | PHASE3 | Baricitinib, corticosteroid |
| AbbVie, Inc. | ABBV | 10 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 12 | PHASE3 | Abrocitinib |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof , 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
ARQ-234 is an investigational monoclonal antibody being developed for the treatment of Atopic Dermatitis (AD), also known as eczema. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
ARQ-234 targets CD200R, a receptor involved in immune regulation. By binding to CD200R, the monoclonal antibody aims to modulate immune responses that contribute to Atopic Dermatitis. This mechanism is being evaluated in early-stage clinical trials.
ARQ-234 is being developed by Arcutis Biotherapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ARQT. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Atopic Dermatitis.
ARQ-234 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1a/1b study is recruiting participants to assess the drug's safety, tolerability, and pharmacokinetics.
ARQ-234 is being studied in a Phase 1a/1b clinical trial registered as NCT07453602. This randomized, double-blind, placebo-controlled study is evaluating single ascending doses and multiple ascending doses of ARQ-234 in approximately 125 participants, including healthy volunteers and individuals with Atopic Dermatitis, at sites in the United States.
ARQ-234 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is a monoclonal antibody targeting CD200R, being developed by Arcutis Biotherapeutics for Atopic Dermatitis.